Onfasprodil

Onfasprodil
Clinical data
Other names	MIJ821
Drug class	NMDA receptor modulator
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 6-{(1S)-2-[(3aR,5R,6aS)-5-(2-Fluorophenoxy)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1-hydroxyethyl}-3-pyridinol;
CAS Number	1892581-29-1;
PubChem CID	118981713;
ChemSpider	115010425;
UNII	C6I8M5AWKP;
KEGG	D12787;
ChEMBL	ChEMBL5095074;
Chemical and physical data
Formula	C20H23FN2O3
Molar mass	358.413 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O([C@@H]1C[C@@]2([C@](C1)(CN(C[C@H](O)C3=CC=C(O)C=N3)C2)[H])[H])C4=C(F)C=CC=C4;
	InChI InChI=1S/C20H23FN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,19,24-25H,7-8,10-12H2/t13-,14+,16+,19-/m0/s1; Key:NEFQLCKWVRZEJA-ZDXGLAPJSA-N;

Onfasprodil (MIJ821) is a drug delivered via intravenous infusion that is designed as a fast-acting treatment for treatment-resistant depression. It works as a negative allosteric modulator of the NMDA receptor subunit 2B (NR2B). The drug is developed by Novartis.^[1]^[2]

^ Gomez-Mancilla, Baltazar; Levy, Jeffrey A.; Ganesan, Subramanian; Faller, Thomas; Issachar, Gil; Peremen, Ziv; Laufer, Offir; Shani-Hershkovich, Revital; Biliouris, Kostas; Walker, Ela; Healy, Mark P.; Sverdlov, Oleksandr; Desai, Sachin; Ghaemi, S. Nassir; Cha, Jang-Ho; Shanker, Y. Gopi (November 2023). "MIJ821 (onfasprodil) in healthy volunteers: First-in-human, randomized, placebo-controlled study (single ascending dose and repeated intravenous dose)". Clinical and Translational Science. 16 (11): 2236–2252. doi:10.1111/cts.13623. PMC 10651655. PMID 37817426.
^ Osaka, Hitoshi; Kanazawa, Tetsufumi (December 2023). "Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms". Psychiatry and Clinical Neurosciences Reports. 2 (4). doi:10.1002/pcn5.157. PMC 11114387. S2CID 265360324.